Apixaban Discontinuation Prior To Major Surgery: Results From A Prospective Single Center Study
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Background
 Current regulatory labeling recommends discontinuing apixaban therapy for at least 48
hours prior to invasive procedures with moderate-high risk of bleeding or at least 24 hours
for invasive procedures with low risk of bleeding.
 Labeling recommendations are based on apixaban pharmacokinetics derived from
controlled studies and may not be representative of real-world conditions.
 Plasma concentrations of <30 ng/mL for direct oral anticoagulants (DOAC) have been
investigated as the minimal concentration prior to surgery or invasive procedure. This
value assumes 3 half-lives or approximately 90% of the maximum concentration of DOAC
eliminated.
 There is currently limited evidence of the proportion of patients on apixaban achieving this
concentration in the real-world setting.

Results
Primary Results

Safety Results

Table 1. Patient demographics

Table 2. Peri-procedural complications and at 7 & 30 day follow-up

Study Objectives
Primary Objective
 Estimate the proportion of patients who achieve a plasma apixaban concentration of <30
ng/mL following at least 48 hours of discontinuation prior to surgery or invasive procedure
Secondary Objectives
 Perioperative and follow up arterial or venous thromboembolic events, major bleeding,
clinically significant non-major bleeding complications. Correlation of apixaban anti-Factor
Xa (FXa) activity and plasma apixaban concentrations at pre-admission and prior to
surgery

Methods

Table 2. a Unrelated to the study, bunlikely related to the study, c nose bleed, d decrease in hemoglobin and required a transfusion,
e two patients had shortness of breath; one patient had right sided weakness and confusion; one patient had a decrease in
hemoglobin and required a transfusion; f one patient had gastrointestinal toxicity and another with anemia. ˥ One patient
experienced both stroke and arrhythmia. - not observed.
Table 1. Summary statistics are presented as % of patients, mean + SD, or median [Q1, Q3], respectively. a Median concentrations [5th,
95th percentile] AA= African American, BID= twice-daily, CrCL= creatinine clearance calculated using Cockcroft-Gault, d/c=
discontinuation, NVAF= non-valvular atrial fibrillation, TIA= transient ischemic attack, VTE= venous thromboembolism

Figure 2. Plasma apixaban concentrations prior to surgery following at least 48
hours of discontinuation

Bioanalytical Results
Figure 4. Correlation between plasma apixaban concentration and apixaban antiFXa activity

Study Design
 Prospective, observational, single-site study in patients receiving treatment with apixaban
for non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) requiring
elective surgery or invasive procedure
 This study was approved by the Thomas Jefferson University IRB (Clinicaltrials.gov ID:
NCT02935751)
Figure 1. Study Schematic

Figure 2. Horizontal line represents the minimum plasma concentration (30 ng/mL). 93.8% (95% CI: 87.8-97) achieved below the minimum
concentrations. Seven patients (6.2%) remained at or above 30 ng/mL (red triangles). Time of discontinuation represents the self-reported
time of apixaban cessation prior to surgery.

Figure 3. Proportion of patients achieving apixaban concentrations < 30 ng/mL by
time of discontinuation
Figure 1. Pre-admission procedures included informed consent, history & physical, anti-FXa activity, plasma apixaban trough
concentration, and pre-operative labs. Plasma pixaban concentration and anti-FXa activity were sampled again the morning prior to
surgery. Post-operative safety follow-up included major bleeding, clinically significant non-major bleeding, VTE, or stroke at 7 and 30
days. FXa= Factor Xa

Conclusions

Study Population
 Adults > 18 years, on long term anticoagulation with apixaban for NVAF or VTE and
undergoing elective major surgery or invasive procedure

Bioanalytical and Statistical Analysis
 Plasma apixaban concentrations were determined using a validated LC-MS/MS (AB Sciex
API 3200MD) in accordance with the FDA guidance on Bionalytical Method Analysis. AntiFXa activity was measured using a quantitative chromogenic assay calibrated for apixaban
(Werfen/IL and Biophen)
 Variables were summarized by means and standard deviations, or if substantially skewed,
as medians with the first and third quartiles. Pearson’s correlation coefficients, linear
regression analysis and Clopper-Pearson confidence intervals were performed on
GraphPad Prism version 8, La Jolla, CA.

Figure 4. Correlation between apixaban concentrations and anti-FXa activity in patients on 2.5 mg BID at pre-admission (A) and
pre-surgery (B) and 5 mg BID at pre-admission (C) and pre-surgery (D). Pearson’s correlation coefficients were used to estimate
correlation between the two variables. Two-sided significance was set at a=0.05. r2= coefficient of determination.

 A large proportion of patients (94%; 95% CI: 88-97%) achieved plasma apixaban concentrations
of <30 ng/mL following at least 48 hours of discontinuation. A greater proportion (>95%) of
patients achieved below 30 ng/mL when apixaban was discontinued for >60 hours.
 No arterial or venous thromboembolic events or major bleeding were observed throughout the
study and follow-up period. Major adverse cardiac events (stroke & arrhythmia) were observed in
5% of patients during the peri-proceudral period, however this was unrelated to the study. Nonmajor bleeding occurred in 1 patient following surgery and at 7 & 30 day follow-up.
 The clinical evidence here suggests a plausible complement to conventional pharmacokinetic
discontinuation strategies based on patient factors and apixaban half-life. Anti-FXa monitoring
may be appropriate, however caution should be raised on its correlation at lower concentrations.
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